Investors & Media

  • Webcast
    Evercore ISI Biopharma Catalyst/Deep Dive Conference
    11/30/17 8:45 am EST
  • Webcast
    BMO 2017 Prescriptions for Success Healthcare Conference
    12/14/17 1:30 pm EST

Company Profile

Ionis is the leading company in RNA-targeted drug discovery and development focused on developing drugs for patients who have the highest unmet medical needs, such as those patients with severe and rare diseases. Using its proprietary antisense technology, Ionis has created a large pipeline of first-in-class or best-in-class drugs, with over three dozen drugs in development. SPINRAZA® (nusinersen) has been approved in the U.S., Europe, Japan, Canada and Brazil for the treatment of spinal muscular atrophy (SMA). Biogen is responsible for commercializing SPINRAZA. Drugs that have successfully completed Phase 3 studies include inotersen , an antisense drug Ionis is developing to treat patients with TTR amyloidosis, and volanesorsen, an antisense drug discovered by Ionis and co-developed by Ionis and Akcea Therapeutics to treat patients with either familial chylomicronemia syndrome or familial partial lipodystrophy. Akcea, an affiliate of Ionis, is a biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. If approved, volanesorsen will be commercialized through Ionis' affiliate, Akcea. Volanesorsen filings for marketing approval have been submitted in the U.S., EU and Canada. Inotersen is progressing toward regulatory filings for marketing authorization. Ionis' patents provide strong and extensive protection for its drugs and technology.

Recent Press Releases

More >>
Date Title and Summary
Toggle Summary Ionis Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference
CARLSBAD, Calif. , Dec. 15, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the 36 th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 7:30 a.m.
Toggle Summary Ionis Pharmaceuticals Licenses IONIS-HTT Rx to Partner Following Successful Phase 1/2a Study in Patients with Huntington's Disease
Dose-dependent Reductions of Mutant Huntingtin Protein Observed Ionis Earns $45 Million License Fee CARLSBAD, Calif. , Dec. 11, 2017 /PRNewswire/ --  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that Roche has exercised its option to license IONIS-HTT Rx following the completion of a
Toggle Summary Ionis Pharmaceuticals to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference
CARLSBAD, Calif. , Dec. 7, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference on Thursday, December 14,
Toggle Summary Ionis Pharmaceuticals Licenses Second Orally Delivered Antisense Drug to Janssen
- IONIS-JBI2-2.5 Rx designed to treat GI autoimmune disease - Ionis Earns $5 Million License Fee from Janssen CARLSBAD, Calif. , Nov. 16, 2017 /PRNewswire/ --  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it has licensed a second orally delivered Generation 2.5 antisense drug to

Upcoming Events

More >>
Date Event Details
Summary Toggle 12/14/17 1:30 pm EST
Summary Toggle 01/08/18 7:30 am PST

For more information requests, please visit our Information Request page.

If you are interested in Ionis Pharmaceuticals’ investment details,
please visit our Investor FAQ page.

Copyright Nasdaq. Minimum 15 minutes delayed.